BASECARE-B (02170) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB233 million, representing a decrease of 22.01% year-on-year. The loss attributable to equity shareholders was RMB223 million, narrowing by 5.7% compared to the previous year. The loss per share was RMB0.8.

For the group, 2025 marked a pivotal year of transitioning gradually from being "R&D and registration-driven" toward "commercial implementation and operational optimization-driven." Amid changes in the external market environment, industry competition, and the company's own developmental stage, the group did not merely pursue revenue scale expansion. Instead, it proactively advanced the optimization of its operational structure, focusing on high-return products, key regional markets, and business directions with long-term platform value.

Throughout this process, while the group experienced periodic revenue fluctuations, its revenue structure, product mix, and regional distribution further improved. Gross profit margin continued to rise, cost control measures proved effective, and both the level of losses and operating cash flow showed sustained improvement.

During the reporting period, the group achieved multiple significant milestones in core product registration, localization efforts, and platform-based business development. In the field of embryo culture, the Geri® time-lapse embryo incubator obtained Chinese registration certification, marking a critical milestone in the localization of high-end embryo culture equipment and laying the foundation for subsequent market introduction and domestic substitution in China. The Gems® product series achieved key registration breakthroughs in the Chinese market, providing a clear pathway for the re-introduction of embryo culture media and generating recurring revenue from repeat purchases.

In the andrology sector, a home-use sperm testing device received approval for market launch, further enhancing the group's product portfolio in pre-assisted reproductive testing scenarios. In genetic testing, the group continued to strengthen its closed-loop capabilities formed by the PGT-A kit, sequencing platform, and analysis software. It also steadily advanced the development of subsequent products such as PGT-M and PGT-SR, reinforcing the company's first-mover advantage and compliance barriers in genetic laboratory settings.